Alexion Pharma Shares Fall After EU Patent Decision

   By Stephen Nakrosis

Shares of Alexion Pharmaceuticals, Inc. (ALXN) are falling in Thursday's after-hours market after it said the European Patent Office decided against granting certain of its patent applications related to Soliris, a treatment for a rare disorder of the nervous system.

At 5:11 p.m. EDT, the company's shares had fallen 3.47% to trade at $96.80. They finished the day's regular trading session with a 2.82% gain, closing at $100.28.

After the bell Thursday, the company said the European Patent Office determined not to grant patent applications "which relate to the pharmaceutical compositions of Soliris (eculizumab) and composition of matter of Soliris."

Alexion said it will evaluate its option to appeal the decision.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

September 05, 2019 17:40 ET (21:40 GMT)

Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Aug 2024 to Sep 2024